United Kingdom

What is the RAPIDe-1 study?

The RAPIDe-1 study is a clinical research study for people who have been diagnosed with hereditary angioedema (HAE).

The main purpose of the study is to find out how effective 3 different doses of the study drug are in relieving symptoms associated with HAE attacks.

Researchers developed the study drug in the form of soft capsules taken by mouth, which are expected to be a more convenient alternative to an injection into a vein or under the skin for resolving HAE attacks.

The study drug, PHVS416, is an investigational* drug designed to stop an HAE attack. The study drug is thought to work by blocking a compound called bradykinin that is responsible for triggering swelling in people with HAE.

*Investigational means that the study drug has not been approved by the regulatory authority in any country to be used for attacks caused by HAE.

The study drug is a soft capsule taken by mouth, which is expected to be a more convenient alternative to an injection into a vein or under the skin for resolving HAE attacks.

Caregiver with Patient

Clinical Study Participation

Clinical research studies help scientists and doctors explore whether a study drug is safe and effective in humans. The data gathered from clinical research helps the development of medical therapies, which may improve your health and the way you receive medical care.

There is no guarantee that the study drug will improve your HAE symptoms, but what researchers learn from the RAPIDe-1 clinical study may lead to better medications for patients with HAE in the future.

The rules and ethics that doctors must follow to practice medicine also apply to clinical research studies. Additional standards called Good Clinical Practice also apply.

Additional Study Details

Patients with HAE are encouraged to contact a local office

Patients with HAE are encouraged to contact a local office to see if they may qualify for this clinical research study. Additionally, patients are recommended to consult their treating health care professional (HCP).

No cost to patients who qualify

Study-related medication and medical care will be provided at no cost to patients who qualify and are enrolled in the study.

Medical care will take place at local hospitals

Medical care will take place at local hospitals and research centres that specialize in the treatment of HAE, and care will be provided by qualified and licensed physicians.